{"name":"Sebela Women's Health Inc.","slug":"sebela-women-s-health-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"LevoCept","genericName":"LevoCept","slug":"levocept","indication":"Vasomotor symptoms associated with menopause","status":"phase_3"},{"name":"VeraCept","genericName":"VeraCept","slug":"veracept","indication":"Congenital adrenal hyperplasia","status":"phase_3"}]}],"pipeline":[{"name":"LevoCept","genericName":"LevoCept","slug":"levocept","phase":"phase_3","mechanism":"LevoCept is a selective estrogen receptor modulator (SERM) that modulates estrogen signaling to treat menopausal symptoms and related conditions in women.","indications":["Vasomotor symptoms associated with menopause","Menopausal bone health and osteoporosis prevention"],"catalyst":""},{"name":"VeraCept","genericName":"VeraCept","slug":"veracept","phase":"phase_3","mechanism":"VeraCept is a medication that works by inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2).","indications":["Congenital adrenal hyperplasia","Cushing's syndrome"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQOTU2QlhjTTlGVHNzR250S2lJY0t5bG54aGpWNXlXblpkaS1tazVPcGZwNGt4UkNZR1gwT0g4TVk5MWxNdzZGbHl4TEZfdE9iWTlxNTZCbnIzaDAtaFJweWxzT3F0bVh2ZDlLdFluWjZSS0tYVHcyZUxWQk53NUpydTRaSDNPbTRvVElubjNKZHphRmVHZUYxRmpPdlNNNnhlZEZLMHFneE10em0zZ1NtblhFbFkxY28wVkZFVTJCX2Z2TE5CejFfekNzSm5SQXRTZ2RpU0dKV2ZueWdnTjFYWUpaOUhGNFBmNnRwVW1yTmRSV2VtRmVhYlpUSjR6T1B0OGs5a0hpUDVDZ2ZjNzBmcWFNVkl3VGRMcWdaTkJjZjFHVFp2?oc=5","date":"2026-01-12","type":"regulatory","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroesophageal Reflux Disease - PR Newswire","headline":"Sebela Pharmaceuticals® Announces Submission of New Drug Application to FDA for Tegoprazan for the Treatment of Gastroes","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-27","type":"trial","source":"PR Newswire","summary":"MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Phase 3 Data Publication in Contraception Honored with Daniel Mishell, Jr. MD Outstanding Article Award at Society of Family Planning Annual Mee","headline":"MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Phase 3 Data Publication in Contraception Honored with Daniel Mi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxPM1NsTkI3X3FGZ0l6YnF6dEhuVWFVZGJ5MGFsTS1oTnlOaWd5c01rcm5LbXFPcWpnWTc5LWdONjZEYzdCOGZHZzh2SDZkcllGMTR3Vzd5TVNfbG9kME9pcDhJUjA2RTI2YmdZZDlSamhvZW9JcDVaNDFjcnllam5RNWM1NHhXdURtdDJOUUtHMXBSamkwYUJkQ2ppRTVFcDhvcHdIbkJsT2U2QzhnQ29zd0w0cVpVVTFoWXF4d0dzNU83QThRcmVfUWtvaWZ6RFVoSkxuVGxvWVNwdkNkZnd4SmxuNURxYzNDbVhTaUxRaWdsZXhveXg2LWNuNWNYSk1RcWNaTVFlQ05Rbk9SWVE?oc=5","date":"2025-10-15","type":"pipeline","source":"PR Newswire","summary":"Sebela Women's Health's MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Named to TIME's List of the Best Inventions of 2025 - PR Newswire","headline":"Sebela Women's Health's MIUDELLA® Hormone-Free Copper Intrauterine System (IUS) Named to TIME's List of the Best Inventi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxORU1PZ1VweTN4dmJhLXQyTm9VSldjU3hIRlRkMFc5TkZBTUJxUFVxRWxpOVFPWUNKTEp1VnhLTVNta1U1NXNsUlhSOVROd2R3Z0dDYWxBcjIzNENrNl9kWVFpZWpBM2dfd2Znd2VSeXkybzFQNWFZbEdydDNLTTA5Qkk2SzlzVjZPYXNEOVVnQTlCZlNzWnpSajI1eGFzUm1RVjhNZ0xfc3gzR3JOMUJobTZoSDlPd2pCZUhEekotbFItcDllX3FoY3E5d3NtSE4wSVExWk8wM1k3dldia1BSOTdjbHJiWnM0azdtN2NsTm1kWTBLb3BJMWlNd3EwV05nYWZlQkZia3FHdzBqcGFzOTROeE1lc1dvN3NST1ZtR3hSbkhWV3RFa1UzSUlJa01y?oc=5","date":"2025-08-07","type":"trial","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 24-Week Maintenance Phase Results - PR Newswire","headline":"Sebela Pharmaceuticals® Announces Successful Completion of Phase 3 TRIUMpH Program of Tegoprazan in GERD with Positive 2","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxPd2tidDEtT1pOd05qWW94ZndJbjJBYTBCR2ZlMVNPZFdOS216cjN2WngxcEhzTTBEZ2lYRGtrcGlqQlFhWlNNMjhTRl9TbE8yQ2I3bHU5enR1eDF2eUJvVktsaGwxUXlIX3UzUThOb0RiZ19lbnY1X1V6YVRpNnoyX1dOUEhCOFplTmJfZW9WUmFJSkRsek00RXA5X20wdE9JVGFuempFdWVaTktzUkpkZDVxc0kteFZRdjNlWGkwNUVNLUpGX3Z0aFlpWnI4S2FhS3NVTzFrTDNKTXlpWTR6RDVqZFB0TGlmUkpmb1dvb2xVd0pZVHh3?oc=5","date":"2025-04-23","type":"trial","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD - PR Newswire","headline":"Sebela Pharmaceuticals® Announces Positive Topline Results from Phase 3 TRIUMpH Program of Tegoprazan in GERD","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE13a0VQRjc5S3N0UF9mTm40cDE3OWFHeEJydk9IbWs2RjBFM0RTUjhIWDZ0YUtQb1lrUlF0VTMwRFFFaWU5Z25PLXZveWpMMHJVVEhkU1hoQnd3MmFPRzlla05MMnJ1S2c2TThPaW4wRmFpSnl2WlU4LTBDQUw?oc=5","date":"2025-03-11","type":"pipeline","source":"Fast Company","summary":"Scientists designed this new copper IUD to be less painful - Fast Company","headline":"Scientists designed this new copper IUD to be less painful","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxQNnBVQkgtU1FuMzJWQnAxU3k2b2tmYkNyRklkUWJsV2MxOF9BRHAzR05FTXFNbXZZZ3BYdVN4dEEzbjJ3MlhCZWdKOFdKUkpzaVFMOE9Cc3RBZmdGODJQbVlDWXMxX0xuVU9WUjlYb2toUGJzYUI0ZHJaNElPLW00NWsxNEwxSWhuaDVqZ1NORXh3YXd0QzByZmtwWjRURHdQWlBlYzNhZXhWRzFZSXFUWGloZUFNTERTWmJEbVFQVnExMXRkOU9oRHQzaUVYTUVtMUhjcG1URXhydER1NFJwVVR4QldZWVI0bDZuM2RFNzByV3A0MUlVT2NORUJfOHBsVlpWREpzdUxYcHhIU1A3N28zbE11X2c?oc=5","date":"2025-02-25","type":"regulatory","source":"PR Newswire","summary":"FDA Approves MIUDELLA®, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years, from Sebela Women's Health Inc. - PR Newswire","headline":"FDA Approves MIUDELLA®, the First Hormone-Free Copper Intrauterine System (IUS) in the U.S. in Over 40 Years, from Sebel","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgJBVV95cUxPREhxX085RWdCaGpXR1ctdHJxZzV2ZGwzVlVadXpIaEEtalpYSVRsLWx2Um5OTE1ac2I2bGFuZUYtQXpmNWwxMjduYzBpVk9HUU9uYkpNRlNjWTAtejJlSXJMU1UtY09fRzNMYmR4cE5OYzlqQmRnYmRZMXVUbjJQTmxnRlJuMnJwOWxscEZ2b2IwWGY0eUI4c2JwQjF1VVpHdnBsY1BJOUlCZ0ExNFpDVk9RVHZDQlVxbnRscDlfREFVc2FSQXpFQzZXeEY0akVsNW9lMDZsTlpRQ3ZpckV6VkpiOGdOTHd6eEpPTHR4RE5RaldsUUJrWHNqbVFWMGgxeTZBRXlEUWlLN0xsQzM0eWFGVFRCSmY1RjBtV1pETERlalBUYlJ6N1BYcWR3b003aUlSWFlB?oc=5","date":"2025-01-24","type":"trial","source":"PR Newswire","summary":"Sebela Women's Health Announces Publication of Phase 3 Pivotal Study Results for the Investigational Copper 175 mm² Intrauterine Device (IUD) in Contraception - PR Newswire","headline":"Sebela Women's Health Announces Publication of Phase 3 Pivotal Study Results for the Investigational Copper 175 mm² Intr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQNk56YjRsUDVmeVBfcmxscE5RZFRvYURlQTAxNEdCc3JmWU91dUhSaFhpUWYzanlHSDZULWc2dWxnTm5hS2tTeENuMjhBQmM2X3pKeVZPWnlBN3B4NDd2S3Ftb1ZEbTB1NmVhRkZsOE1sMERtNUxOOU8zUWpjVng1Z1VKYkJsN3I2aS01WGRicGRCOFVkZVpfbGFJOGktbXFEb1FDd21CenlmMy1PYmNwaVBQTVdYVWNlZ2xXa0NMSUktYXJMSDhqa1JDdFYwbWVIQWVxMXJHYjhKYzRLMmNGSHR4Umx6V1QwWGhtb0oxbjdtbFRmSVRmZ3Zjc1NzZDdwY0lLQVRrZkszQ2pVTWsyMEZ6RHJpTXdKS2hPc01CV2lEdXlUN0JJdjlnNm4yamIyOG1R?oc=5","date":"2023-03-21","type":"pipeline","source":"PR Newswire","summary":"Sebela Women's Health Shares Findings from a Real-World Cost Comparison of Hormonal and Non-hormonal IUD Use Among Privately Insured Individuals in the U.S. - PR Newswire","headline":"Sebela Women's Health Shares Findings from a Real-World Cost Comparison of Hormonal and Non-hormonal IUD Use Among Priva","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPVWItWDBWSW9zaUxVZE9fZk0yTmVYb2pHTkZnU0NoVnJzT3h2Z1pkajJGYy1IZXZLTE5oT2JzcUM0TTJMQU5CYmFPMjd6dUtJRUtLMW1ZN3hGeGQybkZJd3dGSW8xR1A1OEpGSW5kUm03R0l0TjJNSzlPeWlQaWVDaWYwbTNFXzladjdDbE81NWFEUzBUQTZHeGJNXzd3V2plM3lSNnZYdUlFV2RFdU9lcXNXVDZxQQ?oc=5","date":"2022-11-16","type":"pipeline","source":"FemTech World","summary":"Sebela Pharmaceuticals launches women’s health division to develop IUD platform - FemTech World","headline":"Sebela Pharmaceuticals launches women’s health division to develop IUD platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxQQVNVdU10X2ZCVmRfR0FHN2tleVVqZzJlS2UxRldPOVNZTS1wbWNNUkNORURaUi0yMl9OTUw3ZU5FWlh2Zy1rZXZUQ3R1WHl5VnV0M0hLM3FiWEpoQmRLV2E5ZEhMMUlDNEVDZmp2d0RnMmpzUEZWelp3THRmYmJjV3AwQ25JQTcxVVZfdHg1Y0dYM3gxM3Q0MmE2ZE15M3dvQ2x6cG56VVZBcE4zX1NXQnRORkl1aW55WXVpQi1sZUh4SjhtRk45aA?oc=5","date":"2022-10-24","type":"pipeline","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Appoints Victor Parker as Chief Commercial Officer - PR Newswire","headline":"Sebela Pharmaceuticals® Appoints Victor Parker as Chief Commercial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxQbDNIM3Y3dXprb0tCRkRqS2dDWEFGUG5MVVFxcGZUZ29TaHRadDhwZzdBcXJzbnVQTXNfT19Fck9WQTVBSUpKXzlQM0VDdUhaV2ZfMkYzVVZZWUYtRDJvM1NNcV9lWXFscEpmaTZkMlBXM3M4NVlUa1IyclNteHZTeXZXQUN5SVhDdW5DaTBjNnRJUE8wb1Z4WWtPNC1YMmRpRnp1aGZPNFZxU3M0ZTlZTURnTHhtNUVVeDQ1NjdTRFFrQkRZVVhpUGM4TGdxMTk4S19WblhrMkpSWmhsb09kSG1mQWhnU3piV1VjN1RKSU84eHlfSHdianVPaDh0dEJqb1h4MkV3?oc=5","date":"2022-10-19","type":"deal","source":"PR Newswire","summary":"Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Canada - PR Newswire","headline":"Sebela Pharmaceuticals® Acquires Exclusive Licensing Rights to Develop and Commercialize Tegoprazan in the U.S. and Cana","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}